Table 1.

Clinical course and treatment of our Jehovah’s Witness patient

DayHgb, g/dLPlt, ×109/LClinical courseTreatments*
8.4 12 Transient aphasia, bilateral arm and face numbness and weakness, hand clumsiness. MP 375, folic acid 
7.8 16 Neurologic symptoms resolved.  
7.8 24 Rituximab 
7.5 10 Apheresis, Epo 
6.9 Acute transient episode of feeling faint, aphasia, left arm weakness. Apheresis, IVIg 
6.0 10 Neurologic symptoms resolved; no further neurologic abnormalities.  
5.7 15 MP 1000, IVIg 
— — MP 1000, IV iron, rituximab 
6.6 28 MP 1000 
10 — — Gradual improvement. Hallucinations and proximal muscle weakness attributed to corticosteroids. Koate, prednisone 80 
11 7.2 45  
12 7.7 74 Rituximab 
14 9.1 96 Prednisone 40 
16 9.3 109 Discharged to rehabilitation for steroid-induced proximal muscle weakness. Regained strength with physical therapy.  
19 10.0 115 Rituximab 
21 11.8 90  
23 12.7 125  
28 13.0 231 Discharged to home. ADAMTS13, 99%.  
60 — — Return to work.  
DayHgb, g/dLPlt, ×109/LClinical courseTreatments*
8.4 12 Transient aphasia, bilateral arm and face numbness and weakness, hand clumsiness. MP 375, folic acid 
7.8 16 Neurologic symptoms resolved.  
7.8 24 Rituximab 
7.5 10 Apheresis, Epo 
6.9 Acute transient episode of feeling faint, aphasia, left arm weakness. Apheresis, IVIg 
6.0 10 Neurologic symptoms resolved; no further neurologic abnormalities.  
5.7 15 MP 1000, IVIg 
— — MP 1000, IV iron, rituximab 
6.6 28 MP 1000 
10 — — Gradual improvement. Hallucinations and proximal muscle weakness attributed to corticosteroids. Koate, prednisone 80 
11 7.2 45  
12 7.7 74 Rituximab 
14 9.1 96 Prednisone 40 
16 9.3 109 Discharged to rehabilitation for steroid-induced proximal muscle weakness. Regained strength with physical therapy.  
19 10.0 115 Rituximab 
21 11.8 90  
23 12.7 125  
28 13.0 231 Discharged to home. ADAMTS13, 99%.  
60 — — Return to work.  

Days begin with hospital admission on day 1.

Epo, recombinant human erythropoietin; Hgb, hemoglobin concentration; MP, methylprednisolone (and prednisone); Plt, platelet count.

*

Doses, regimens: apheresis, plasmapheresis with albumin replacement; Epo, 10 000 U then 20 000 U, 3 times per week; folic acid, 1 mg per day; IVIg, 70 g (1 g/kg); IV iron, ferrous gluconate, 125 mg IV daily; Koate, 2000 U (30 U/kg), given once; MP, milligrams per day; rituximab, 375 mg/m2.

Close Modal

or Create an Account

Close Modal
Close Modal